Literature DB >> 17378975

Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes.

Kausik K Ray1, Christopher P Cannon.   

Abstract

Acute coronary syndromes involve a complex interplay between the vessel wall, inflammatory cells, and the coagulation cascade. Statins possess beneficial effects that are independent of low-density lipoprotein cholesterol lowering and that have favorable effects on inflammation, the endothelium, and the coagulation cascade. There is now accumulating evidence that these lipid-independent pleiotropic effects are clinically relevant in the management of acute coronary syndromes.

Entities:  

Year:  2007        PMID： 17378975     DOI： 10.1007/s11936-007-0050-1

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN： 1092-8464


  41 in total

1.  HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.

Authors:  Birgit Assmus; Carmen Urbich; Alexandra Aicher; Wolf K Hofmann; Judith Haendeler; Lothar Rössig; Ioakim Spyridopoulos; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Circ Res       Date:  2003-04-03       Impact factor: 17.367

2.  Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.

Authors:  M Vasa; S Fichtlscherer; K Adler; A Aicher; H Martin; A M Zeiher; S Dimmeler
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

3.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

4.  Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways.

Authors:  Masato Eto; Toshiyuki Kozai; Francesco Cosentino; Hana Joch; Thomas F Lüscher
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

5.  Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease.

Authors:  Ingebjørg Seljeflot; Serena Tonstad; Ingvar Hjermann; Harald Arnesen
Journal:  Atherosclerosis       Date:  2002-05       Impact factor: 5.162

6.  Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study.

Authors:  G Rioufol; G Finet; I Ginon; X André-Fouët; R Rossi; E Vialle; E Desjoyaux; G Convert; J F Huret; A Tabib
Journal:  Circulation       Date:  2002-08-13       Impact factor: 29.690

7.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

Review 8.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-07       Impact factor: 29.690

9.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.

Authors:  O Hernández-Perera; D Pérez-Sala; J Navarro-Antolín; R Sánchez-Pascuala; G Hernández; C Díaz; S Lamas
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

10.  HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.

Authors:  Wolfgang Dichtl; Jozef Dulak; Matthias Frick; Hannes F Alber; Severin P Schwarzacher; Mikko P S Ares; Jan Nilsson; Otmar Pachinger; Franz Weidinger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311
View more
  2 in total

1.  Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial.

Authors:  Giuseppe Mancia; Gianfranco Parati; Miriam Revera; Grzegorz Bilo; Andrea Giuliano; Fabrizio Veglia; Gaetano Crepaldi; Alberto Zanchetti
Journal:  BMJ       Date:  2010-03-25

2.  Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy.

Authors:  Raul Altman
Journal:  Thromb J       Date:  2007-08-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.